Results 81 to 90 of about 25,328 (173)

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals

Frontiers in Oncology
IntroductionConsolidation durvalumab post chemo-radiotherapy (CRT) has been demonstrated to improve survival in locally advanced non-small-cell lung cancer (NSCLC).
Valérie Labrie, Judith Lefebvre, Catherine Labbé, Kevin Jao, Mandy Malick, Serge Simard, Nicole Bouchard   +6 more
doaj   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, Volume 159, Issue 11, Page 2766-2777, 1 December 2026.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

Journal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet, O. Moranne, D. Daubin, X. Quantin, P. Palassin, T. Kanouni, A. T. J. Maria, the MonRIO network (Montpellier Réseau Immuno‐Oncologie), Q. Thomas, P. Witkowski Durand Viel, C. Coustal, S. Faure, L. Meunier, L. Hountondji, R. Altwegg, C. Lesage, A. Lamoureux, G. Mouterde, S. Fabre, G. Taieb, F. Esselin, X. Ayriginac, C. Travert, B. Roch, F. Roubille, I. Raingeard, M. Le Quintrec, K. Dessaix, F. Garo, O. Moranne, J‐L. Faillie, P. Palassin, K. Klouche, B. Jauzelon, S. Bisiou, P. Rozier, A. TJ Maria   +36 more
wiley   +1 more source

De‐Escalation of Neoadjuvant Treatment for HER2‐Positive Breast Cancer

International Journal of Cancer, Volume 159, Issue 10, Page 2393-2402, 15 November 2026.
ABSTRACT With improved prognosis in early HER2‐positive breast cancer, safely de‐escalating treatment is increasingly investigated to minimize overtreatment. This article focuses on neoadjuvant de‐escalation strategies for HER2‐positive breast cancer.
Yiyin Ma, Dedian Chen, Sheng Huang
wiley   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3972-3981, November 2026.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Efficacy of Durvalumab Consolidation Therapy After Sequential Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer—Experience from the Daily Hospital of Clinic for Pulmonology, University Clinical Center of Serbia

Biomedicines
Background/Objectives: Patients with stage III non-small cell lung cancer represent a very heterogeneous group of patients. In the past, the standard of care for patients with inoperable stage III non-small cell lung cancer was concurrent or sequential ...
Vesna Ćeriman Krstić, Natalija Samardžić, Spasoje Popević, Ruža Stević, Branislav Ilić, Milija Gajić, Nikola Čolić, Katarina Lukić, Brankica Milošević Maračić, Bojana Poparić Banđur, Biljana Šeha, Damir Radončić, Jelena Milin Lazović   +12 more
doaj   +1 more source

Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An, Junfeng Zhao, Wenjie Chen, Ying Li, Yifei Yan, Chen Zhou, Ruyue Li, Xiujing Yao, Xue Dong, Xingying Yang, Yongjuan Hu, Jiaxuan Chen, Chuankun Han, Yingrui Bai, Yali Xu, Yintao Li   +15 more
wiley   +1 more source

Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS–STING–STAT3 survival axis

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Abstract Background Ovarian cancer (OC) remains the most lethal gynaecological malignancy, and acquired resistance to PARP inhibitors such as olaparib represents a major clinical challenge. Although dysregulation of iron metabolism has been implicated in tumorigenesis, the specific role of the iron exporter SLC40A1 (ferroportin, FPN) in mediating ...
Jiagui Song, Zhengyang Guo, Decao Yang, Ping Yu, Yinjia Li, Zhuhui Yuan, Xiaojuan Ma, Xianlong Li, Hongyan Guo, Lixiang Xue, Tong Liu   +10 more
wiley   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, Volume 48, Issue 11, Page 3152-3172, November 2026.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, Volume 159, Issue 9, Page 2262-2277, 1 November 2026.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source